Stockreport

Relay Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Highlights [Yahoo! Finance]

Relay Therapeutics, Inc.  (RLAY) 
PDF Initiated dose expansion cohort for RLY-2608 600mg BID + fulvestrant in patients with PI3Ka-mutated, HR+/HER2- metastatic breast cancer Updated RLY-2608 600mg BID + f [Read more]